SYK vs TMO
Stryker Corp. and Thermo Fisher Scientific Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | SYK | TMO |
|---|---|---|
| Revenue | $25.1B | $44.6B |
| Net income | $3.2B | $6.7B |
| Gross margin | 64.0% | 57.1% |
| Net margin | 12.9% | 15.0% |
| Return on equity | 17.8% | 13.0% |
| Diluted EPS | $8.40 | $17.74 |
| Dividend / share | $1.56 | $1.72 |
| Payout ratio | 39.6% | 9.5% |
| Free cash flow | $4.3B | $6.3B |
| Equity | $11.7B | $53.4B |
| Net debt / equity | 0.53× | 0.62× |
| Current ratio | 1.89× | 1.89× |
| Revenue CAGR 5y | 11.8% | 6.7% |
| Profit CAGR 5y | 15.2% | 1.0% |
TMO bills 1.8× the revenue of SYK, and keeps more of each dollar of revenue as profit (15.0% against 12.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | SYK | TMO |
|---|---|---|
| FY2025 | $25.1B | $44.6B |
| FY2024 | $22.6B | $42.9B |
| FY2023 | $20.5B | $42.9B |
| FY2022 | $18.4B | $44.9B |
| FY2021 | $17.1B | $39.2B |
| FY2020 | $14.4B | $32.2B |
| FY2019 | $14.9B | $25.5B |
| FY2018 | $13.6B | $24.4B |
| FY2017 | $12.4B | $20.9B |
| FY2016 | $11.3B | $18.3B |
Net income by year
Bottom line
| Fiscal year | SYK | TMO |
|---|---|---|
| FY2025 | $3.2B | $6.7B |
| FY2024 | $3.0B | $6.3B |
| FY2023 | $3.2B | $6.0B |
| FY2022 | $2.4B | $7.0B |
| FY2021 | $2.0B | $7.7B |
| FY2020 | $1.6B | $6.4B |
| FY2019 | $2.1B | $3.7B |
| FY2018 | $3.6B | $2.9B |
| FY2017 | $1.0B | $2.2B |
| FY2016 | $1.6B | $2.0B |
Advertisement
AdSense · Rectangle 336×280